Modern tools of biological investigation give us opportunities to develop drugs much more efficiently. The president of Europes most important trials organisation explains how these opportunities can and must be exploited to start [more]
Patients are losing out because the rules governing research are designed to restrain rather than facilitate. Its got to change, says Roger Stupp, who is frustrated that 10 years after helping set a new standard [more]
Since the concept of personalised cancer therapies first emerged, the picture has become so much more complex and challenging. “If it were not for the great variability between individuals, medicine might as well be a [more]
Many of the worst economic and bureaucratic burdens that have proved such a deterrent to multi-country clinical trials look set to be addressed with the overhaul of the EU Clinical Trials Directive, but should we [more]
Journalists who write about their own cancer journeys are able to convey important insights in a language that people understand and are eager to read It is not surprising that a lot of journalists [more]
The potential for personalising lung cancer therapies is expanding rapidly. The challenge now is how to turn that potential into reality as fast as possible so patients can reap the benefits. A network of cancer [more]
The bureaucratic obstacles that often prevent European cancer patients from joining clinical trials in other Member States came under the spotlight recently in the case of a young woman with melanoma. Download full article
Jaap Verweij, head of medical oncology and an early-phase trials expert at the Erasmus University Medical Centre in Rotterdam invites you to reappraise the way we are going about improving cancer therapies. Download full article
Europe has money, human resources and a basic-science base that produces world-leading cancer research. Why, then, aren’t these assets being translated into clinical advances? Download full article
Selected reports edited by Hannah Brown Download full article
Clinical research activity may be plummeting in the rest of Europe, but in France they’re determined to substantially increase the numbers of hospitals and patients involved in clinical trials starting with a strategic trial [more]